SMAD2 and cancer: We demonstrate that the selective activation of SMAD3 signaling in hypoxia occurs in a wide variety of cancers and that SMAD2 and SMAD3 exert dichotomous roles in cell invasion, in which SMAD3 drives the invasive properties of cancer cells in vitro and in vivo.